slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 26,731-26,760
Pages 1,349
Rows per page 30
Beat
26,731-26,760 of 40,452
16
D-Wave | Investor Day Presentation Deck | 133 slidesD-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
17
D-Wave | Investor Day Presentation Deck | 133 slidesD-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
18
D-Wave | Investor Day Presentation Deck | 133 slidesD-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
19
The slide uses a directional arrow graphic to show these factors feeding into the D-Wave brand.D-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
20
D-Wave | Investor Day Presentation Deck | 133 slidesD-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
06
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
07
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
Scientific diagram illustrating the mechanism of antigen presentation and T cell maturation.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a biological diagram to explain the 'problem' of immune evasion in cancer therapy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
11
The diagram uses a funnel-like or layered process flow to map biological mechanisms to specific immune outcomes.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
12
The slide uses a process flow diagram to illustrate the 8-step manufacturing timeline.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide uses a red border to highlight the RENB-DC11 row as the superior alternative.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The diagram illustrates a complex supply chain process involving biopsy, manufacturing, and clinical administration.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a combination of a process diagram and dot plots to validate the model's performance.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
The slide presents two bar charts (weight and volume) and a grid of tumor photographs as visual proof of concept.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
Includes visual evidence of tumor size alongside quantitative bar charts with statistical significance markers.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The table shows 0/3 incidence of metastasis/ascites in the RENB-DC11 group compared to high incidence in control groups.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide presents two bar charts comparing control, tumor, tumor+mock, and tumor+TD groups under different treatment conditions (IL2 vs aCD16).Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
N=2-3 sample size indicated at bottom left.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The slide demonstrates efficacy of RENB-DC11 in stimulating immune response (IFNg production) in a tumor model.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses immunohistochemistry (brown staining) to visualize CD4+ T-cells, quantified in the bar chart.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
The slide uses immunohistochemistry images and a corresponding bar chart to demonstrate efficacy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate clinical validation.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
12
The slide uses a side-by-side comparison of two market segments, each with a big number metric and supporting clinical/regulatory context.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
13
Includes a biological diagram illustrating the RAS protein state transition and mutation impact.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
14
The chart shows lower IC50 values for the Q61X mutation group, suggesting higher sensitivity to the drug.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
15
Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
16
Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
17
The slide uses a 'before-after' visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit